Short filmsShort film, 1:09 · 2 of 28
The Hype Man Who Starts Asking Questions
He came to cheer every decision. Then he heard what the numbers actually meant.
Finding cancer and finding advanced precancer are two different numbers. In one screening round, Cologuard Plus detects most cancers but fewer than half of advanced precancers.
The evidence behind it
The full caption
In an examination room, a patient brings an exuberant supporter to his conversation with a physician. The supporter starts asking questions when the discussion separates cancer detection from advanced-precancer detection. The film identifies Cologuard Plus, the next-generation stool DNA test, and contrasts its detection of existing cancer with its lower detection of advanced precancer in one screening round. The conversation turns toward colonoscopy’s ability to find and remove precancerous polyps.
The Cologuard Plus figures in this film come from the published BLUE-C study and describe people with the respective finding in one screening round. They do not establish equivalent long-term prevention. BLUE-C was funded by Exact Sciences, the manufacturer, and included company-affiliated authors.
Colonoscopy can miss lesions and carries risks, including bleeding and perforation. Stool-based screening is a guideline-supported option, especially when it helps someone complete screening; a positive stool test requires follow-up colonoscopy. Discuss suitability and a screening plan you can complete with your clinician.
Scene and message summary, not a word-for-word transcript.